Tech Company Financing Transactions
IMU Biosciences Funding Round
IMU Biosciences, based in London, secured $14.6 million in funding from Molten Ventures and private investors.
Transaction Overview
Company Name
Announced On
1/24/2024
Transaction Type
Venture Equity
Amount
$14,615,000
Round
Series A
Investors
Molten Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate its roadmap, including its novel CytAtlas® platform, foster new strategic partnerships and projects, conduct immune research, and expand its operations into the Boston/Cambridge, MA, area.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
City Tower, 40 Basinghall Street
London, EC2V 5DE
UK
London, EC2V 5DE
UK
Phone
Undisclosed
Website
Email Address
Overview
The foundation of IMU is built on the belief that deep systems level immunophenotyping at a population level, powered by the latest advancements in AI and Machine Learning, will lead to a totally new understanding of the immune system and help develop the next-generation precision medicines. IMU is fulfilling this vision with its proprietary discovery engine, and building a comprehensive Immune Atlas that covers the spectrum of health and disease, to advance precision medicine.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 1/24/2024: Vivifi India Finance venture capital transaction
Next: 1/24/2024: Naq venture capital transaction
Share this article
News on VC Transactions
We do our best to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs